NOV O COM IN THE U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Albert R. DiPiero et al.

Filed: November 21, 2001

Application No.: 09/990,123

For: HEALTH PLAN MANAGEMENT METHOD AND APPARATUS

Attorney Docket No: 40920/1:2

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS
~WASHINGTON, D.C. 20231

RECEIVED
NOV 0 7 2002
GROUP 3600

Enclosed for filing in the above-referenced application are the following:

Information Disclosure Statement

International Search Report

(6) Cited References

Return postcard

The United States Patent and Trademark Office is hereby authorized to charge any additional fees which may be required in connection with filing of these papers, or credit overpayment, to Account No. 19-4455. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

W. Glen Johnson Reg. No. 39,525

Date: Oct. 29, 2002

STOEL RIVES LLP 900 SW Fifth Avenue, Suite 2600 Portland, Oregon 97204-1268 Telephone: (206) 386-7661 Facsimile: (206) 386-7500

Attorney Docket No.: 40920/1:2

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231, ON THE DATE SHOWN BELOW:

Typed or Printed Name of Person Signing Certificate)

(Signature)

10/29/02

(Date)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Albert R. DiPiero et al.

Filed: November 21, 2001

Application No.: 09/990,123

RECEIVED

For: HEALTH PLAN MANAGEMENT METHOD AND APPARATUS

NOV 0 7 2002 GROUP 3600

Attorney Docket No: 40920/1:2

INFORMATION DISCLOSURE STATEMENT

TO THE COMMISSIONER FOR PATENTS:

Pursuant to their duty of disclosure, applicant encloses copies of the documents listed

on the accompanying Form PTO-1449.				
1.	This information disclosure statement is being submitted:			
	a.		Within three months of the filing date of the above-identified application or within three months of the date of entry of the national stage, or before the mailing date of the first Office action on the merits, whichever event occurs last. (No statement under 37 CFR 1.97(e) is required.)	
	b.		After the period set forth in paragraph 1a, but before the mailing date of either a final action or a notice of allowance. (Check box i. or ii.)	
		i.	A \$240.00 information disclosure statement submission fee set forth in 37 CFR 1.17(p) is enclosed.	
		ii.	A statement specified by 37 CFR 1.97(e) is set forth below.	
	c.		After the mailing date of a final action or notice of allowance and on or before payment of an issue fee. A statement specified by 37 CFR 1.97(e) is set forth below. A petition requesting consideration of the information disclosure statement and the \$130.00 petition fee set forth in 37 CFR 1.17(i) are enclosed.	
2.	\boxtimes	The att	torney or agent signing below hereby states that:	
		\boxtimes	each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a	

	counterpart foreign application not more than three months prior to the filing of the information disclosure statement.
	no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement.
3	Applicant(s) set forth below concise explanations of the relevance of each document not in the English language and/or selected document(s) in the English language.
	W. Glen Johnson Registration No. 39,525
	Date: $(KF, O, 7)$ OOO

W. Glen Johnson Stoel Rives LLP 900 SW Fifth Avenue Suite 2600 Portland, OR 97204

Tel: (206) 386-7661 Fax: (206) 386-7500

Attorney Docket No.: 40920/1:2

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.